Pneumologie 2023; 77(S 01): S45
DOI: 10.1055/s-0043-1760974
Abstracts

The German Asthma Net: Anti-IL5(R) therapy reduces disease burden in a real-life severe asthma cohort in comparison to patients on maintenance OCS therapy

Authors

  • C Bal

    1   Division of Pulmonology, Department of Internal Medicine II, Medical University Vienna, Austria

  • S Korn

    2   Thoraxklinik Heidelberg; Ikf Pneumologie Mainz

  • K Milger-Kneidinger

    3   Department of Medicine V, LMU University Hospital Munich; Comprehensive Pneumology Center (Cpc-M), Member of the German Center for Lung Research (Dzl); Medizinische Klinik V

  • D Skowasch

    4   Uniklinikum Bonn; Medizinische Klinik Ii; Kardiologie, Pneumologie

  • C Schulz

    5   Klinik und Poliklinik für Innere Medizin Ii; Pneumologie; Department of Internal Medicine II, University Hospital Regensburg, Regensburg

  • S Zehetmayer

    6   Department for Medical Statistics, Informatics and Intelligent Systems, Medical University of Vienna, Austria

  • C Taube

    7   Universitätsklinikum Essen – Ruhrlandklinik; Klinik für Pneumologie; Pneumologie Universitätsmedizin Essen

  • E Hamelmann

    8   Klinik für Kinder- und Jugendmedizin Bielefeld; Universitätsklinikum Owl, Universität Bielefeld; Kinderzentrum Bethel, Evangelisches Klinikum Bethel, University Bielefeld, Bielefeld

  • R Buhl

    9   Universität Mainz; Med. Klinik; Schwerpunkt Pneumologie, III.

  • M Idzko

    10   Universitätsklinik für Innere Medizin Ii; Abteilung für Pulmonologie; Ebene 6/L
Further Information
Also available at
 

348 of 2283 patients with severe asthma>12 yrs. included in the real-life, long-term German Asthma Net registry used anti-IL5(R) antibody therapy (mepolizumab, benralizumab, reslizumab), (57±13 yrs., 57% female, BMI 27±6 kg/m², 5±5 exacerbations per year, ACQ score 2.6±1.5), compared to 329 corticosteroid (OCS) dependent patients (49±17 yrs., 55% female, BMI 27±6 kg/m², 4±4 exac./year, ACQ 2.6±1.4).

Zoom
Abb. 1  

Baseline ACQ, mAQLQ and FEV1 values were comparable, patients on IL5(R) received more OCS at baseline (6±11 vs 4±10 mg, p=0.021). In comparison to systemic corticosteroid dependent patients without biological therapy, patients on anti-IL5(R) therapy showed significantly better asthma control (ACQ-5 score), better quality of life (mAQLQ score), and an increase in FEV1 in% predicted (all mean+SD). OCS dependency (median [IQR]) was also significantly reduced:

Conclusion Real-life, severe asthma patients treated with anti-IL5(R) biologics showed long-term benefits regarding pivotal outcome and disease control parameters including asthma control, quality of life, lung function, and corticosteroid use, highlighting beneficial effects previously documented in controlled studies in a real-life severe asthma cohort. These effects appear to be superior to those obtained with OCS treatment.



Publication History

Article published online:
09 March 2023

© 2023. Thieme. All rights reserved.

Georg Thieme Verlag
Rüdigerstraße 14, 70469 Stuttgart, Germany